🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge
Demo corpus. Scores are computed on a select set of biomedical paper/datasets and may be inaccurate for papers outside this corpus — DataRank relies on network effects that improve with scale. We aim to expand this into a fully open resource pending additional funding.

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

The Lancet Respiratory Medicine(2020)10.1016/s2213-2600(20)30079-5Source: DataRank Database

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study is a research paper published in The Lancet Respiratory Medicine (2020). On theSindex it has a DataRank of 1.4. It has been cited 10,679 times. Its calibrated FAIR score is 16/100.

N/A
1.4DataRank · unranked
1.4
Open Access10679 citations · base score 9.3
Cite:
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Abstract

BackgroundAn ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in December, 2019, in Wuhan, China. Information about critically ill patients with SARS-CoV-2 infection is scarce. We aimed to describe the clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia.MethodsIn this single-centered, retrospective, observational study, we enrolled 52 critically ill adult patients with SARS-CoV-2 pneumonia who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital (Wuhan, China) between late December, 2019, and Jan 26, 2020. Demographic data, symptoms, laboratory values, comorbidities, treatments, and clinical outcomes were all collected. Data were compared between survivors and non-survivors. The primary outcome was 28-day mortality, as of Feb 9, 2020. Secondary outcomes included incidence of SARS-CoV-2-related acute respiratory distress syndrome (ARDS) and the proportion of patients requiring mechanical ventilation.FindingsOf 710 patients with SARS-CoV-2 pneumonia, 52 critically ill adult patients were included. The mean age of the 52 patients was 59·7 (SD 13·3) years, 35 (67%) were men, 21 (40%) had chronic illness, 51 (98%) had fever. 32 (61·5%) patients had died at 28 days, and the median duration from admission to the intensive care unit (ICU) to death was 7 (IQR 3-11) days for non-survivors. Compared with survivors, non-survivors were older (64·6 years [11·2] vs 51·9 years [12·9]), more likely to develop ARDS (26 [81%] patients vs 9 [45%] patients), and more likely to receive mechanical ventilation (30 [94%] patients vs 7 [35%] patients), either invasively or non-invasively. Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax. 37 (71%) patients required mechanical ventilation. Hospital-acquired infection occurred in seven (13·5%) patients.InterpretationThe mortality of critically ill patients with SARS-CoV-2 pneumonia is considerable. The survival time of the non-survivors is likely to be within 1-2 weeks after ICU admission. Older patients (>65 years) with comorbidities and ARDS are at increased risk of death. The severity of SARS-CoV-2 pneumonia poses great strain on critical care resources in hospitals, especially if they are not adequately staffed or resourced.FundingNone.

Data sources & pipeline
Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring
Enrichment:Pending

FAIR Checklist

Context only (not used in score)
Findable (1/2)
  • Has DOI
Accessible (1/2)
  • Open Access
Interoperable (0/2)
    Reusable (0/3)

      FAIR checklist signals are shown for context only and do not affect DataRank scoring.

      16FAIR score
      F Findable
      20
      A Accessible
      30
      I Interoperable
      13
      R Reusable
      0
      Top 98% by FAIRLLM-assessed⚠ abstract only
      Estimated from the abstract only. The agent couldn't read this paper's full text, so body-dependent criteria (data-availability statement, formats, license) are inferred. For a confident score, upload the PDF or supply full text →

      Calibrated FAIR score — a parallel quality metric, independent of the DataRank citation score. See the full evaluation →

      DataRank Breakdown

      Base Score 100%Citation Network 0%

      Base Score Contribution

      1.4

      From this paper's citation signal

      Citation Network Contribution

      0

      Citation network not refreshed for this result

      This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

      Learn more about DataRank methodology →
      Why this DataRank?

      DataRank blends this paper's own citation count with the influence of the papers that cite it. Here, roughly 100% comes from its base citations and 0% from the citation network.

      Base score B(p)
      log1p(citation_count) — grows sub-linearly, so a paper with 1,000 citations is not 10× a paper with 100.
      Network N(p)
      Σ over citers of log1p(Cq) ÷ max(outdegreeq, 1). Being cited by a highly-cited paper with few references counts most.
      Damping factor d = 0.85
      DataRank = (1−d)·B(p) + d·N(p) — the two cards above are each already multiplied by their share.
      Self-citations excluded
      Citers sharing any OpenAlex author ID with this paper are filtered out before the network sum.

      Citers are pulled from OpenAlex sorted by cited_by_count:descand capped per paper, so when the cap binds we keep the highest-signal references and the score is reproducible across reruns.

      Read the full methodology →

      Authors (17)

      Yuan Yu,Jiqian Xu,Huaqing Shu,Jia'an Xia,Hong LiuORCID

      Related Papers (10)

      New England Journal of Medicine(2020)
      co-cited
      10.1056/nejmoa2002032
      The Lancet Respiratory Medicine(2020)
      co-citedsame journal
      10.1016/s2213-2600(20)30076-x